Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Molecular Templates Inc (MTEM)

Molecular Templates Inc (MTEM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 288,637
  • Shares Outstanding, K 36,769
  • Annual Sales, $ 13,290 K
  • Annual Income, $ -30,290 K
  • 60-Month Beta 2.88
  • Price/Sales 22.50
  • Price/Cash Flow N/A
  • Price/Book 3.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.24
  • Prior Year 0.36
  • Growth Rate Est. (year over year) -161.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.82 +15.98%
on 06/06/19
8.58 -7.81%
on 05/30/19
-0.20 (-2.47%)
since 05/24/19
3-Month
5.12 +54.49%
on 03/27/19
8.58 -7.81%
on 05/30/19
+2.36 (+42.52%)
since 03/26/19
52-Week
3.19 +147.96%
on 12/24/18
8.58 -7.81%
on 05/30/19
+2.44 (+44.61%)
since 06/26/18

Most Recent Stories

More News
Oppenheimer Gathers Life Science Leaders And Investors For Montauk Emerging Life Sciences Summit

Oppenheimer & Co. Inc. ("Oppenheimer") - a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) - will host its Montauk Emerging Life Sciences Summit at Gurney's...

ALPN : 4.50 (unch)
OPY : 26.83 (+1.55%)
MTEM : 7.85 (+0.76%)
Will Molecular Templates to Surge Higher?

As of late, it has definitely been a great time to be an investor Molecular Templates.

MTEM : 7.85 (+0.76%)
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference

Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies...

MTEM : 7.85 (+0.76%)
Molecular Templates, Inc. Reports First Quarter 2019 Financial Results

Molecular Templates, Inc. (Nasdaq: MTEM, "Molecular" or "Molecular Templates"), a clinical-stage oncology company focused on the discovery and development of the company's proprietary engineered toxin...

MTEM : 7.85 (+0.76%)
Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MTEM : 7.85 (+0.76%)
Translational Research in Oncology (TRIO) Partners With Molecular Templates for First-In-Human Phase I Study for MT-5111

Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced it has partnered with Molecular Templates (Nasdaq: MTEM) to conduct its First-in-Human study...

MTEM : 7.85 (+0.76%)
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2

Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies...

MTEM : 7.85 (+0.76%)
Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cousins Properties Incorporated...

VSM : 51.51 (+0.21%)
CUZ : 36.00 (-2.81%)
TLND : 37.92 (+0.93%)
ARDX : 2.47 (-1.59%)
MTEM : 7.85 (+0.76%)
MTOR : 23.47 (+2.31%)
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

ALPN : 4.50 (unch)
OTIC : 2.55 (-0.86%)
MTEM : 7.85 (+0.76%)
TCDA : 34.77 (-1.08%)
ATNM : 0.25 (-3.85%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 19.96 (-2.92%)
ACRX : 2.14 (-2.28%)
ALPN : 4.50 (unch)
OTIC : 2.55 (-0.86%)
MTEM : 7.85 (+0.76%)
TCDA : 34.77 (-1.08%)
ATNM : 0.25 (-3.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MTEM with:

Business Summary

Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered...

See More

Key Turning Points

2nd Resistance Point 8.29
1st Resistance Point 8.07
Last Price 7.85
1st Support Level 7.71
2nd Support Level 7.57

See More

52-Week High 8.58
Last Price 7.85
Fibonacci 61.8% 6.52
Fibonacci 50% 5.88
Fibonacci 38.2% 5.25
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar